Proteomic Profiling of a Biomimetic Drug Delivery Platform
Current delivery platforms are typically designed for prolonged circulation that favors superior accumulation of the payload in the targeted tissue. The design of efficient surface modifications determines both a longer circulation time and targeting abilities of particles. The optimization of synthesis protocols to efficiently combine targeting molecules and elements that allow for an increased circulation time can be challenging and almost impossible when several functional elements are needed. On the other hand, in the last decade, the development of bioinspired technologies was proposed as a new approach with which to increase particle safety, biocompatibility and targeting, while maintaining the synthesis protocols simple and reproducible. Recently, we developed a new drug delivery system inspired by the biology of immune cells called leukolike vector (LLV) and formed by a nanoporous silicon core and a shell derived from the leucocyte cell membrane. The goal of this study is to investigate the protein content of the LLV. Here we report the proteomic profiling of the LLV and demonstrate that our approach can be used to modify the surface of synthetic particles with more than 150 leukocyte membraneassociated proteins that determine particle safety, circulation time and targeting abilities towards inflamed endothelium..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Current drug targets - 16(2015), 13, Seite 1540-1547 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Claudia Corbo [VerfasserIn] |
|---|
| Links: |
|---|
| BKL: |
|---|
| doi: |
10.2174/1389450115666141109211413 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1960891464 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1960891464 | ||
| 003 | DE-627 | ||
| 005 | 20230516154130.0 | ||
| 007 | tu | ||
| 008 | 160206s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1389450115666141109211413 |2 doi | |
| 028 | 5 | 2 | |a PQ20160430 |
| 035 | |a (DE-627)OLC1960891464 | ||
| 035 | |a (DE-599)GBVOLC1960891464 | ||
| 035 | |a (PRQ)b2373-ddb0a1147a0f5f33c87c575e93df24ec600e86ba00cb1c742a5c338efc3504870 | ||
| 035 | |a (KEY)0401769220150000016001301540proteomicprofilingofabiomimeticdrugdeliveryplatfor | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DNB |
| 084 | |a PHARM |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 0 | |a Claudia Corbo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Proteomic Profiling of a Biomimetic Drug Delivery Platform |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Current delivery platforms are typically designed for prolonged circulation that favors superior accumulation of the payload in the targeted tissue. The design of efficient surface modifications determines both a longer circulation time and targeting abilities of particles. The optimization of synthesis protocols to efficiently combine targeting molecules and elements that allow for an increased circulation time can be challenging and almost impossible when several functional elements are needed. On the other hand, in the last decade, the development of bioinspired technologies was proposed as a new approach with which to increase particle safety, biocompatibility and targeting, while maintaining the synthesis protocols simple and reproducible. Recently, we developed a new drug delivery system inspired by the biology of immune cells called leukolike vector (LLV) and formed by a nanoporous silicon core and a shell derived from the leucocyte cell membrane. The goal of this study is to investigate the protein content of the LLV. Here we report the proteomic profiling of the LLV and demonstrate that our approach can be used to modify the surface of synthetic particles with more than 150 leukocyte membraneassociated proteins that determine particle safety, circulation time and targeting abilities towards inflamed endothelium. | ||
| 700 | 0 | |a Alessandro Parodi |4 oth | |
| 700 | 0 | |a Michael Evangelopoulos |4 oth | |
| 700 | 0 | |a David A. Engler |4 oth | |
| 700 | 0 | |a Rise K. Matsunami |4 oth | |
| 700 | 0 | |a Anthony C. Engler |4 oth | |
| 700 | 0 | |a Roberto Molinaro |4 oth | |
| 700 | 0 | |a Shilpa Scaria |4 oth | |
| 700 | 0 | |a Francesco Salvatore |4 oth | |
| 700 | 0 | |a Ennio Tasciotti |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug targets |d Hilversum [u.a.] : Bentham Science Publ., 2000 |g 16(2015), 13, Seite 1540-1547 |w (DE-627)339868791 |w (DE-600)2064859-5 |w (DE-576)435515284 |x 1389-4501 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2015 |g number:13 |g pages:1540-1547 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.2174/1389450115666141109211413 |3 Volltext |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1389-4501&volume=16&issue=13&spage=1540 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | b | k | |a 44.40 |q AVZ |
| 951 | |a AR | ||
| 952 | |d 16 |j 2015 |e 13 |h 1540-1547 | ||